ATE530197T1 - Medizinische zusammensetzungen zur angiogenese- therapie - Google Patents

Medizinische zusammensetzungen zur angiogenese- therapie

Info

Publication number
ATE530197T1
ATE530197T1 AT07021738T AT07021738T ATE530197T1 AT E530197 T1 ATE530197 T1 AT E530197T1 AT 07021738 T AT07021738 T AT 07021738T AT 07021738 T AT07021738 T AT 07021738T AT E530197 T1 ATE530197 T1 AT E530197T1
Authority
AT
Austria
Prior art keywords
angiogenic
gene
effect
contain
active ingredient
Prior art date
Application number
AT07021738T
Other languages
English (en)
Inventor
Ryuichi Morishita
Hiromi Koike
Tadashi Tanabe
Motokuni Aoki
Original Assignee
Anges Mg Inc
Ryuichi Morishita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc, Ryuichi Morishita filed Critical Anges Mg Inc
Application granted granted Critical
Publication of ATE530197T1 publication Critical patent/ATE530197T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT07021738T 2000-06-27 2001-06-27 Medizinische zusammensetzungen zur angiogenese- therapie ATE530197T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000192480 2000-06-27
JP2000388624 2000-12-21

Publications (1)

Publication Number Publication Date
ATE530197T1 true ATE530197T1 (de) 2011-11-15

Family

ID=26594742

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01943840T ATE395071T1 (de) 2000-06-27 2001-06-27 Pharmazeutische zubereitungen zur angiogenese- therapie
AT07021738T ATE530197T1 (de) 2000-06-27 2001-06-27 Medizinische zusammensetzungen zur angiogenese- therapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01943840T ATE395071T1 (de) 2000-06-27 2001-06-27 Pharmazeutische zubereitungen zur angiogenese- therapie

Country Status (10)

Country Link
US (2) US20030171287A1 (de)
EP (2) EP1889633B1 (de)
KR (1) KR100798566B1 (de)
CN (1) CN1274365C (de)
AT (2) ATE395071T1 (de)
AU (2) AU6633801A (de)
CA (1) CA2413768A1 (de)
DE (1) DE60134021D1 (de)
NZ (1) NZ523613A (de)
WO (1) WO2002000258A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778826B2 (en) * 1999-10-29 2004-12-23 Anges Mg, Inc. Gene therapy for diabetic ischemic disease
US20050260582A1 (en) * 2001-02-13 2005-11-24 Hirofumi Kai Cell proliferation inhibitors comprising ets transcription factor or gene encoding the same
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
AU2003302590B2 (en) * 2002-12-02 2008-11-06 Anges Mg, Inc. Compositions for treating or preventing angiogenesis-dependent symptoms
WO2005021045A1 (ja) * 2003-08-29 2005-03-10 Anges Mg, Inc. 針無注射器を用いた皮膚疾患の遺伝子治療
CA2557884C (en) * 2004-03-09 2011-12-06 Tohoku Technoarch Co., Ltd. An agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US7608416B2 (en) * 2004-12-07 2009-10-27 The Trustees Of The University Of Pennsylvania Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
JP5725489B2 (ja) 2008-06-27 2015-05-27 公立大学法人大阪市立大学 医療用組成物および医療用キット
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
WO2011014563A1 (en) * 2009-07-29 2011-02-03 Vatrix Medical, Inc. Tissue stabilization for heart failure
US20120156170A1 (en) 2009-08-31 2012-06-21 Tadashi Tanabe Drug composition for angiogenesis therapy
EP2485687A1 (de) * 2009-10-09 2012-08-15 Vatrix Medical, Inc. Chemische in-vivo-stabilisierung empfindlicher plaque
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
EP2709711B8 (de) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Beschichtete ballons zur blutgefässstabilisierung
US9283241B2 (en) 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
CN105682676B (zh) 2013-10-22 2020-10-23 赫利世弥斯株式会社 利用肝细胞生长因子的两种以上的异构体的肌萎缩性侧索硬化症预防或治疗用组合物
BR112016029008B1 (pt) 2014-06-12 2023-05-02 Tx Medic Ab Uso de sulfato de dextrana com peso molecular médio abaixo de 10000 da para induzir a angiogênese em um sujeito
BR112021000722A2 (pt) 2018-07-19 2021-05-04 Helixmith Co., Ltd. composições farmacêuticas liofilizadas para terapia gênica de dna nu
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0727490B1 (de) * 1994-04-28 2006-06-28 Tanabe, tadashi Humane prostacyclinsynthase
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JP3058828B2 (ja) * 1996-03-15 2000-07-04 株式会社巴川製紙所 電子写真トナー用ポリエステル系樹脂、該樹脂の製造方法及び該樹脂を用いた電子写真用トナー
US5785965A (en) * 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
US20030219380A1 (en) * 1997-11-07 2003-11-27 Annie Fong Method of determining an efficacious dose of a drug
AUPP459998A0 (en) * 1998-07-09 1998-07-30 Monash University Modulation of haemopoietic cell activity and inflammation via the ets-1 gene and agents useful for same
DE19940012A1 (de) 1999-08-24 2001-03-08 Karin Faerber Neues Mittel aus mindestens zwei Komponenten, das zum einen Gefäßneubildung (Neoangiogense) induziert des weiteren jedoch auch Gefäßverschlüsse (Restenosen) verhindert, das Verfahren seiner Herstellung und seine Verwendung
JP2001199903A (ja) * 1999-11-09 2001-07-24 Eizo Mori 核酸含有複合体
DE60128540T2 (de) * 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
US6533541B1 (en) * 2001-12-04 2003-03-18 Honeywell International, Inc. High energy particle arrestor for air turbine starters

Also Published As

Publication number Publication date
ATE395071T1 (de) 2008-05-15
AU2001266338B2 (en) 2006-11-09
NZ523613A (en) 2005-02-25
CN1274365C (zh) 2006-09-13
AU6633801A (en) 2002-01-08
EP1300158A4 (de) 2005-04-13
EP1300158B1 (de) 2008-05-14
AU2001266338B8 (en) 2006-12-14
US20030171287A1 (en) 2003-09-11
EP1300158B9 (de) 2008-11-19
WO2002000258A8 (en) 2003-01-23
CN1446105A (zh) 2003-10-01
EP1300158A1 (de) 2003-04-09
DE60134021D1 (de) 2008-06-26
EP1889633B1 (de) 2011-10-26
EP1889633A1 (de) 2008-02-20
KR100798566B1 (ko) 2008-01-28
US7994151B2 (en) 2011-08-09
US20100240735A1 (en) 2010-09-23
KR20030014391A (ko) 2003-02-17
CA2413768A1 (en) 2002-01-03
WO2002000258A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
ATE530197T1 (de) Medizinische zusammensetzungen zur angiogenese- therapie
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
ATE407675T1 (de) Aspirin enthaltende medizinische zusammensetzungen
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
ES2181017T3 (es) Composicion farmaceutica que contiene una sustancia promotora de osteogenesis y un polietilenglicol.
DK1251846T3 (da) C4-Carbonattaxaner
DE50012571D1 (de) Biotin enthaltende galenische formulierung
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
SE0002729D0 (sv) Novel compound form
DE60134234D1 (de) Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
PL368040A1 (en) Substituted 4-aminocyclohexanol derivatives
EP1385948A4 (de) Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2003040119A8 (fr) Inhibiteurs de l'angiogenese
WO2002100346A3 (en) (r, r'),(r',s')-amphetaminil, compositions and uses thereof
WO2002100342A3 (en) (s, s'), (s, r')-amphetaminil, compositions and uses thereof
DK1330253T3 (da) Anvendelse af bioaktiv fraktion af kourindestillat ("Go-mutra") som en biofremmer for antiinfektionsmidler, anticancermidler og næringsmidler

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties